<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OPP</journal-id>
<journal-id journal-id-type="hwp">spopp</journal-id>
<journal-id journal-id-type="nlm-ta">J Oncol Pharm Pract</journal-id>
    <journal-title>Journal of Oncology Pharmacy Practice</journal-title>
<issn pub-type="ppub">1078-1552</issn>
<issn pub-type="epub">1477-092X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1078155212458133</article-id>
<article-id pub-id-type="publisher-id">10.1177_1078155212458133</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Vitale</surname><given-names>Felice V</given-names></name>
<xref ref-type="corresp" rid="corresp1-1078155212458133"/>
</contrib>
<aff id="aff1-1078155212458133">Division of Medical Oncology, San Vincenzo Hospital, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Malaponte</surname><given-names>Emilia</given-names></name>
</contrib>
<aff id="aff2-1078155212458133">Division of Medical Oncology, San Vincenzo Hospital, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Calì</surname><given-names>Stefania</given-names></name>
</contrib>
<aff id="aff3-1078155212458133">Division of Medical Oncology, San Vincenzo Hospital, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Antonelli</surname><given-names>Giovanna</given-names></name>
</contrib>
<aff id="aff4-1078155212458133">Division of Medical Oncology, San Vincenzo Hospital, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Panebianco</surname><given-names>Vincenzo</given-names></name>
</contrib>
<aff id="aff5-1078155212458133">Division of Surgical Oncology, San Vincenzo Hospital, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Blandino</surname><given-names>Rosario</given-names></name>
</contrib>
<aff id="aff6-1078155212458133">Division of Surgical Oncology, San Vincenzo Hospital, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ferraù</surname><given-names>Francesco</given-names></name>
</contrib>
<aff id="aff7-1078155212458133">Division of Medical Oncology, San Vincenzo Hospital, Italy</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1078155212458133">Felice Vito Vitale, Division of Medical Oncology, San Vincenzo Hospital, Taormina 98039, Italy. Email: <email>f.vitale@videobank.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>202</fpage>
<lpage>207</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec15-1078155212458133"><title>Background:</title><p>Mitomycin and irinotecan are widely used in the treatment of colorectal cancer, furthermore both of these drugs are active agents against nonsmall cell lung cancer and their combination has shown synergism in preclinical studies. The aim of the study was to evaluate the efficacy and safety of mitomycin- and irinotecan-based chemotherapy combination in patients with advanced nonsmall cell lung cancer progressing after previous antineoplastic therapies.</p></sec>
<sec id="sec16-1078155212458133"><title>Methods:</title><p>Thirty-one consecutive patients suffering from nonsmall cell lung cancer, who underwent mitomycin- plus irinotecan-based chemotherapy as salvage treatment after failure of at least two previous systemic treatments, were retrospectively identified in our database. Between September 2003 and March 2011, 31 patients with histologically proven stage IIIB or IV nonsmall cell lung cancer, received mitomycin 5 mg/m<sup>2</sup> on day 1 followed by irinotecan 150 mg/m<sup>2</sup> on day 2. Cycles were repeated at 2-week interval.</p></sec>
<sec id="sec17-1078155212458133"><title>Results:</title><p>A total of 164 cycles of treatment were given with a median of five per patient (range 1–10). The objective responses included partial response in 6 patients (19.3%), stable disease in 4 (13%), and progressive disease in 21 (67.7%). Median time to disease progression was 4 months, and median survival was 9+ months. Twelve patients (38%) reached 1-year survival. Grade 3–4 toxicities occurred in seven patients (22.5%), mainly myelosuppression (neutropenia, anemia, and thrombocytopenia), mucositis, and diarrhea. No treatment-related death was recorded.</p></sec>
<sec id="sec18-1078155212458133"><title>Conclusion:</title><p>The mitomycin- and irinotecan-based combination chemotherapy seems to be tolerated and active in this subset of heavily pretreated patients with advanced nonsmall cell lung cancer. However, evaluation or recruitment of a larger number of patients would be needed to provide more adequate data on safety and activity of the described combination.</p></sec>
</abstract>
<kwd-group>
<kwd>Nonsmall cell lung cancer</kwd>
<kwd>mitomycin</kwd>
<kwd>irinotecan</kwd>
<kwd>combination chemotherapy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1078155212458133" sec-type="intro"><title>Introduction</title>
<p>The prognosis of patients with stage IIIB and IV disease treated with conventional chemotherapies is less than optimal.<sup><xref ref-type="bibr" rid="bibr1-1078155212458133">1</xref></sup> Currently, several compounds such as chemotherapy drugs (platinum analogs, vinorelbine, gemcitabine, taxanes, and pemetrexed), monoclonal antibodies (bevacizumab), or epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) have an undisputed place as first or second-line treatment in patients with advanced nonsmall cell lung cancer (NSCLC).<sup><xref ref-type="bibr" rid="bibr2-1078155212458133">2</xref>,<xref ref-type="bibr" rid="bibr3-1078155212458133">3</xref></sup> On the contrary, the efficacy and safety of chemotherapy as third-line therapy, or beyond, for advanced NSCLC is unclear.<sup><xref ref-type="bibr" rid="bibr4-1078155212458133">4</xref>,<xref ref-type="bibr" rid="bibr5-1078155212458133">5</xref></sup> Irinotecan (CPT) and its active metabolite, SN-38 (7-ethyl-10hydroxycamptothecin), block the enzyme topoisomerase I. Topoisomerase I catalyzes DNA cleavage and is often found in high levels in malignant tissue.<sup><xref ref-type="bibr" rid="bibr6-1078155212458133">6</xref></sup> Mitomycin (MMC) is a bioreductive alkylating drug inhibiting DNA replication by means of interstrand cross-linking.<sup><xref ref-type="bibr" rid="bibr7-1078155212458133">7</xref></sup> During the past decades, MMC has been widely employed, in combination with other chemotherapy agents, for treatment of NSCLC and phase I–II studies have reported also on CPT clinical activity against NSCLC.<sup><xref ref-type="bibr" rid="bibr8-1078155212458133">8</xref><xref ref-type="bibr" rid="bibr9-1078155212458133"/><xref ref-type="bibr" rid="bibr10-1078155212458133"/><xref ref-type="bibr" rid="bibr11-1078155212458133"/><xref ref-type="bibr" rid="bibr12-1078155212458133"/>–<xref ref-type="bibr" rid="bibr13-1078155212458133">13</xref></sup> The sequential administration of MMC and CPT has a deep rationale, because the two drugs appear to have synergism in preclinical studies.<sup><xref ref-type="bibr" rid="bibr14-1078155212458133">14</xref>,<xref ref-type="bibr" rid="bibr15-1078155212458133">15</xref></sup> As MMC upregulates the level of topoisomerase I, the target of CPT, a strong rationale exists for their sequential administration in malignancies.<sup><xref ref-type="bibr" rid="bibr16-1078155212458133">16</xref></sup></p>
<sec id="sec2-1078155212458133" sec-type="subjects"><title>Patients and methods</title>
<p>The medical records of 31 NSCLC patients who were treated with sequential MMC and CPT combination, between September 2003 and February 2011, were retrospectively reviewed.</p>
</sec>
<sec id="sec3-1078155212458133"><title>Inclusion criteria</title>
<p>Based on the charts review findings, the patients had to meet the following criteria to be eligible for the treatment: histologically confirmed NSCLC treated with at least two previous antineoplastic therapies, age &lt;75 year old; an adequate baseline hepatic function defined as a total bilirubin level ≤1.2 mg/dL; AST (aspartate aminotransferase) and ALT (alanine aminotransferase) &lt; twice the upper limits of normal; an adequate baseline bone marrow reserve defined as neutrophil count ≥1500/mm<sup>3</sup>; platelet count ≥100,000 µL; hemoglobin level &gt;9 g/dL; adequate renal function defined as serum creatinine concentration &lt;1.4 mg/dL; measurable disease at baseline by computed tomography (CT) scans; performance status (PS) ≤2, according to the Eastern Cooperative Oncology Group (ECOG) scale; an expected survival of at least 3 months.<sup><xref ref-type="bibr" rid="bibr17-1078155212458133">17</xref></sup> All the eligible patients were treated after giving informed consent in accordance with the institutional regulations. Before the chemotherapy was started, all patients had a physical examination, a complete blood count, serum chemistries (liver and renal function tests and electrolytes), CT scanning of the abdomen, chest, and pelvis along with brain.</p>
</sec>
<sec id="sec4-1078155212458133"><title>Treatment plan and toxicity</title>
<p>Patients were planned to receive MMC 5 mg/m<sup>2</sup> on day 1, followed by CPT 150 mg/m<sup>2</sup> on day 2. However, a 20% dose reduction to the MMC dose on the first cycle was permitted if the patient experienced greater than grade 2 myelotoxicity with previous chemotherapy.<sup><xref ref-type="bibr" rid="bibr18-1078155212458133">18</xref></sup> Cycles were repeated at 2-week interval if the absolute granulocyte count was ≥1500/dL, platelets ≥100,000/dL, and hemoglobin level &gt;9 g/dL. Furthermore, in the event of any other relevant (grade ≥2) nonhematologic toxicity the chemotherapy session was delayed. In the event of any grade 3 toxicity or grade &gt;2 myelotoxicity, the treatment was interrupted and the dose of MMC and CPT reduced by 20%. Treatment was kept on until disease progression or unacceptable grade 4 toxicity or if the patient refused to continue treatment. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE).<sup><xref ref-type="bibr" rid="bibr19-1078155212458133">19</xref></sup></p>
</sec>
<sec id="sec5-1078155212458133"><title>Evaluation criteria</title>
<p>An evaluation of response was planned after six courses of chemotherapy by means of Total Body CT scan. Response evaluation to treatment was based on RECIST criteria.<sup><xref ref-type="bibr" rid="bibr20-1078155212458133">20</xref></sup> However, the patients who were withdrawn from the trial before this time because of rapidly progressive malignant disease and/or clinical picture worsening, were considered nonresponders, so that all of the patients were considered evaluable for response and toxicity profile in an intent-to-treat analysis. Some authors hypothesize that 50 mg/m<sup>2</sup> might be the maximum MMC tolerated cumulative dose.<sup><xref ref-type="bibr" rid="bibr21-1078155212458133">21</xref></sup> So, no more than 10 combination chemotherapy cycles were administered. For patients categorized as responders or achieving a stable disease after 10 cycle of chemotherapy, if deemed appropriate or as necessary, a CPT-based monochemotherapy could be restarted but MMC was discontinued. The time to tumor progression (TTP) was estimated from the day of study entry to the day of documented disease progression, and survival from the day of study entry to the date of death or last follow-up.</p>
</sec>
</sec>
<sec id="sec6-1078155212458133" sec-type="results"><title>Results</title>
<sec id="sec7-1078155212458133"><title>Patients characteristics</title>
<p>From September 2003 to March 2011, 31 patients were administered sequential MMC- and CPT-based chemotherapy (<xref ref-type="table" rid="table1-1078155212458133">Table 1</xref>). The treatment was done on an outpatient basis. Twenty-eight patients were males and three females with a median age of 60 years (range 37–64). Thirty patients (97%) had distant metastases (stage IV disease) and one patient (3%) locally advanced disease (stage IIIB disease). As regards histological subtypes, they were as follows: 16 adenocarcinoma (51.6%), 8 squamous carcinoma (25.8%), 1 large cell carcinoma (3.2%), 6 carcinoma, other, and unspecified (19.3%). Most patients [<italic>n</italic> = 25(80.6%)] had an ECOG PS of 2. A median of 3 previous lines of systemic treatments had been administered per patient (range 2–5).Twenty-eight out of 31 patients had been administered cisplatin- or carboplatin-based first-line chemotherapy. The patients received 164 cycles of therapy in total (range 1–10; median per patient 5); 137/164 (83.5%) cycles were administered in accordance with the planned dose (<xref ref-type="table" rid="table1-1078155212458133">Table 1</xref>).
<table-wrap id="table1-1078155212458133" position="float"><label>Table 1.</label><caption><p>Main characteristics of the patients.</p></caption>
<graphic alternate-form-of="table1-1078155212458133" xlink:href="10.1177_1078155212458133-table1.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td><italic>Total</italic></td>
<td>31</td>
</tr>
<tr>
<td><italic>Age</italic> (<italic>year</italic>)</td>
</tr>
<tr>
<td> Median</td>
<td>57</td>
</tr>
<tr>
<td> Range</td>
<td>37–74</td>
</tr>
<tr>
<td><italic>Sex</italic> (<italic>M/F</italic>)</td>
<td>3/28</td>
</tr>
<tr>
<td><italic>Histological subtypes</italic></td>
</tr>
<tr>
<td> Adenocarcinoma</td>
<td>16</td>
</tr>
<tr>
<td> Squamous carcinoma</td>
<td>8</td>
</tr>
<tr>
<td> Large cell carcinoma</td>
<td>1</td>
</tr>
<tr>
<td> Carcinoma, other, and unspecified</td>
<td>6</td>
</tr>
<tr>
<td><italic>ECOG PS</italic></td>
</tr>
<tr>
<td> 0</td>
<td>0</td>
</tr>
<tr>
<td> 1</td>
<td>6</td>
</tr>
<tr>
<td> 2</td>
<td>25</td>
</tr>
<tr>
<td><italic>Stage</italic></td>
</tr>
<tr>
<td> III</td>
<td>1</td>
</tr>
<tr>
<td> IV</td>
<td>30</td>
</tr>
<tr>
<td><italic>Cycles</italic></td>
</tr>
<tr>
<td> Total</td>
<td>164</td>
</tr>
<tr>
<td> Median per patient</td>
<td>5</td>
</tr>
<tr>
<td> Range</td>
<td>1–10</td>
</tr>
<tr>
<td> Planned dose</td>
<td>137/164</td>
</tr>
<tr>
<td><italic>MMC dose at first cycle</italic></td>
</tr>
<tr>
<td> 5 mg/m<sup>2</sup></td>
<td>29</td>
</tr>
<tr>
<td> 4 mg/m<sup>2</sup></td>
<td>2</td>
</tr>
<tr>
<td><italic>Number of previous antiblastic treatments</italic></td>
</tr>
<tr>
<td> Median per patient</td>
<td>3</td>
</tr>
<tr>
<td> Range</td>
<td>2–5</td>
</tr>
<tr>
<td><italic>Previous antineoplastic regimens</italic></td>
</tr>
<tr>
<td> Cisplatin/gemcitabine</td>
<td>13</td>
</tr>
<tr>
<td> Cisplatin/vinorelbine</td>
<td>3</td>
</tr>
<tr>
<td> Carboplatin/gemcitabine</td>
<td>1</td>
</tr>
<tr>
<td> Carboplatin/vinorelbine</td>
<td>9</td>
</tr>
<tr>
<td> Carboplatin/paclitaxel</td>
<td>3</td>
</tr>
<tr>
<td> Carboplatin/paclitaxel/gemcitabine</td>
<td>1</td>
</tr>
<tr>
<td> Vinorelbine/gemcitabine</td>
<td>7</td>
</tr>
<tr>
<td> Docetaxel/gemcitabine</td>
<td>8</td>
</tr>
<tr>
<td> Vinorelbine monotherapy</td>
<td>10</td>
</tr>
<tr>
<td> Gemcitabine monotherapy</td>
<td>8</td>
</tr>
<tr>
<td> Paclitaxel monotherapy</td>
<td>2</td>
</tr>
<tr>
<td> Gefitinib monotherapy</td>
<td>4</td>
</tr>
<tr>
<td> Erlotinib monotherapy</td>
<td>9</td>
</tr>
<tr>
<td> Docetaxel monotherapy</td>
<td>19</td>
</tr>
<tr>
<td> Pemetrexed monotherapy</td>
<td>2</td>
</tr>
<tr>
<td> Etoposide monotherapy</td>
<td>1</td>
</tr>
<tr>
<td><italic>First-line cisplatin or carboplatin based chemotherapy</italic></td>
</tr>
<tr>
<td> Yes</td>
<td>28</td>
</tr>
<tr>
<td> No</td>
<td>3</td>
</tr>
<tr>
<td><italic>Response to first-line chemotherapy</italic></td>
</tr>
<tr>
<td> Partial response</td>
<td>19</td>
</tr>
<tr>
<td> Complete response</td>
<td>2</td>
</tr>
<tr>
<td> Stationary disease</td>
<td>6</td>
</tr>
<tr>
<td> Progressive disease</td>
<td>4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1078155212458133">
<p>ECOG: Eastern Cooperative Oncology Group; MMC: mitomycin; and PS: performance status.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec8-1078155212458133"><title>Tumor response</title>
<p><xref ref-type="table" rid="table2-1078155212458133">Table 2</xref> shows response rate, TTP, and survival of the 31 treated patients. Six patients achieved a partial response with a response rate of 19.3%. Tumor response occurred in lung (five patients), in mediastinal lymph nodes (two patients), in liver (one patient), and intra-abdominal lymph nodes (one patient). Three of the responders had an ECOG PS of 2. Stable disease was found in 4 patients (13%), and progressive disease was documented in the remaining 21 (67.7%). The median time to disease progression was 4 months (range 1–20). The 1-year survival rate was 38% and median survival was 9+ months (range 1–21) being three patients still alive at last follow-up on September 2011. Of further interest, all the six patients achieving a partial response experienced a partial response even after the first-line chemotherapy (three patients had been treated with cisplatin plus gemcitabine; two patients with vinorelbine plus gemcitabine; and one patient with carboplatin plus vinorelbine). As to response after the second-line therapy, two patients experienced partial response (they were treated with docetaxel-based monotherapy and carboplatin- plus vinorelbine-based combination chemotherapy, respectively), one patient showed almost complete response (administered gefitinib), two patients had stable disease (treated with docetaxel plus gemcitabine), and another had progressive disease (treated with docetaxel).
<table-wrap id="table2-1078155212458133" position="float"><label>Table 2.</label><caption><p>Activity of MMC and CPT combination in 31 pretreated NSCLC patients.</p></caption>
<graphic alternate-form-of="table2-1078155212458133" xlink:href="10.1177_1078155212458133-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Overall response</th>
<th>Number of patients (%)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Partial response</td>
<td>6 (19.3%)</td>
</tr>
<tr>
<td>Stable disease</td>
<td>4 (13%)</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>21 (67.7%)</td>
</tr>
<tr>
<td>Median time to progression: months(range)</td>
<td>4 (1–20)</td>
</tr>
<tr>
<td>Median survival: months(range)</td>
<td>9+ (1–21)</td>
</tr>
<tr>
<td>1-year survival</td>
<td>12 (38%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1078155212458133">
<p>NSCLC: nonsmall cell lung cancer; CPT: irinotecan; and MMC: mitomycin.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-1078155212458133"><title>Toxicities</title>
<p>Toxicities are shown in <xref ref-type="table" rid="table3-1078155212458133">Table 3</xref>. Grade 3–4 toxicities occurred in seven patients (22.5%). The incidence of grade 3 or 4 CTCAE hematologic toxicity per patient was neutropenia 12.8%, thrombocytopenia 3.2%, and anemia 3.2%. Four patients experienced febrile neutropenia (12.8%). Overall, nonhematologic grade 3–4 toxicities amounted to 16% (nausea/vomiting 3.2%; diarrhea 6.4%; oral mucositis 3.2%; and esophagitis 3.2%). Seven patients were admitted due to diarrhea (one patient), febrile neutropenia (four patients), esophagitis (one patient), and mucositis oral (one patient). The longest follow-up reached 21 months and no evidence of long-term MMC related toxicity was recorded. Furthermore, no treatment-related death occurred.
<table-wrap id="table3-1078155212458133" position="float"><label>Table 3.</label><caption><p>Toxicities of MMC/CPT combination per patient (no. 31).</p></caption>
<graphic alternate-form-of="table3-1078155212458133" xlink:href="10.1177_1078155212458133-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="3">Toxicities</th>
<th colspan="4">CTCAE grade</th>
</tr>
<tr><th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
<tr><th>Number of patients (%)</th>
<th>Number of patients (%)</th>
<th>Number of patients (%)</th>
<th>Number of patients (%)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Neutropenia</td>
<td>4 (12.9)</td>
<td>1 (3.2)</td>
<td>3 (9.6)</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>2 (6.4)</td>
<td>–</td>
<td>1 (3.2)</td>
<td>–</td>
</tr>
<tr>
<td>Anemia</td>
<td>12 (38.7)</td>
<td>3 (9.6)</td>
<td>1 (3.2)</td>
<td>–</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>2 (6.4)</td>
<td>3 (9.6)</td>
<td>1 (3.2)</td>
<td>–</td>
</tr>
<tr>
<td>AST and/or ALT increased</td>
<td>3 (9.6)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3 (9.6)</td>
<td>4 (12.9)</td>
<td>1 (3.2)</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>2 (6.4)</td>
<td>11 (35.4)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mucositis oral</td>
<td>–</td>
<td>–</td>
<td>1 (3.2)</td>
<td>–</td>
</tr>
<tr>
<td>Esophagitis</td>
<td>–</td>
<td>–</td>
<td>1 (3.2)</td>
<td>–</td>
</tr>
<tr>
<td>Allergic reaction (MMC)</td>
<td>1 (3.2)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1078155212458133">
<p>CTCAE: Common Terminology Criteria for Adverse Events; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CPT: irinotecan; and MMC: mitomycin.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec10-1078155212458133" sec-type="discussion"><title>Discussion</title>
<sec id="sec11-1078155212458133"><title>Response to treatment</title>
<p>At present patients suffering from advanced and/or metastatic NSCLC can be offered several active and innovative treatments.<sup><xref ref-type="bibr" rid="bibr2-1078155212458133">2</xref>,<xref ref-type="bibr" rid="bibr3-1078155212458133">3</xref></sup> Nonetheless, some of these need to be included into a chemotherapy combination to be more effective in treating NSCLC (i.e. bevacizumab and pemetrexed).<sup><xref ref-type="bibr" rid="bibr22-1078155212458133">22</xref>,<xref ref-type="bibr" rid="bibr23-1078155212458133">23</xref></sup> On the contrary, other ones (biologicals) such as erlotinib, gefitinib, or ALK inhibitors are effective also as single drug against NSCLC. Unfortunately, a few patients have biological characteristics that make them suitable for those latter ones.<sup><xref ref-type="bibr" rid="bibr24-1078155212458133">24</xref></sup> However, overall, these recent and innovative therapeutic tools have significantly prolonged NSCLC sufferers’ survival.<sup><xref ref-type="bibr" rid="bibr23-1078155212458133">23</xref></sup> Therefore, a considerable number of patients are potentially able to undergo several lines of systemic treatments. Of interest over the past decades, combination chemotherapy regimens including MMC were employed mostly as front or, less frequently, second-line therapy in NSCLC patients.<sup><xref ref-type="bibr" rid="bibr25-1078155212458133">25</xref><xref ref-type="bibr" rid="bibr26-1078155212458133"/>–<xref ref-type="bibr" rid="bibr27-1078155212458133">27</xref></sup> The few available historical literature data concerning the activity of MMC in salvage chemotherapy combinations, mainly with vindesine, report a poor response rate (ranging from 0% to 19%) and overall response rate (about 10%).<sup><xref ref-type="bibr" rid="bibr27-1078155212458133">27</xref></sup> Currently, MMC is not considered a drug of choice for NSCLC treatment. Still, there are no literature available data on activity of MMC- or CPT-based monochemotherapy in heavily treated NSCLC patients. The present report focuses on a MMC-based regimen delivered to patients who had received previously at least two prior antineoplastic therapies. Our experience can lead to some considerations: an unusual way of combining two old chemotherapy drugs may likely improve their efficacy; also heavily treated NSCLC patients, provided that they have a good PS, might have a clinical benefit when treated with MMC and CPT combination; patients not responsive to first-line platinum derivates based chemotherapy are unlikely to take advantage of sequential MMC and CPT combination. So that the response to first-line chemotherapy and the PS prior to initiation of a third (or beyond)-line chemotherapy may be relevant to predict clinical benefit to NSCLC patients. These considerations have been already well underlined by Girard et al. in their retrospective analysis including 173 patients who received third-line treatment. The authors identified disease previous response to first or second-line chemotherapy as being the most important predictive factor of benefit to further therapy for heavily treated patients. Other factors taken into account were a PS of 0 or 1, no disease outside the lungs, age less than 70 years along with lack of smoking history.<sup><xref ref-type="bibr" rid="bibr4-1078155212458133">4</xref></sup></p>
</sec>
<sec id="sec12-1078155212458133"><title>Treatment-related toxicity</title>
<p>With respect to the tolerability profile, we report a not-negligible toxicity. Notably, four patients encountered febrile neutropenia (12.8%) so that a prophylactic use of granulocyte colony stimulating factors should be considered when administering the aforementioned combination. The MMC and CPT sequential administration seemed to be beneficial for some of the patients scrutinized in this study. It can be speculated that this advantage may stem from the fact that the patients’ tumors were likely biologically prone to response to chemotherapy drugs. The development of new antineoplastic drugs to treat NSCLC, generally so-called targeted molecules, leading to an almost personalized therapy, makes difficult to propose further large investigational trials to test the activity and safety of MMC and CPT combination in NSCLC patients. Nonetheless, based on the reported data, the described combination might be taken into account in treating patients suffering from advanced NSCLC (even if heavily treated) and cancer progression after previous antineoplastic therapies, provided that they have a fairly good PS.</p>
</sec>
</sec>
</body>
<back>
<sec id="sec13-1078155212458133"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec14-1078155212458133"><title>Conflicts of interest</title>
<p>The authors declare that there is no conflict of interest.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-1078155212458133"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Heighway</surname><given-names>J</given-names></name></person-group>. <article-title>Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer</article-title>. <source>The Oncologist</source> <year>2010</year>; <volume>15</volume>: <fpage>1034</fpage>–<lpage>1042</lpage>.</citation></ref>
<ref id="bibr2-1078155212458133"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katzel</surname><given-names>JA</given-names></name><name><surname>Fanucchi</surname><given-names>MP</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group>. <article-title>Recent advances of novel targeted therapy in non-small cell lung cancer</article-title>. <source>J Hematol Oncol</source> <year>2009</year>; <volume>2</volume>: <fpage>1</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr3-1078155212458133"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirsh</surname><given-names>V</given-names></name></person-group>. <article-title>Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach</article-title>. <source>Curr Oncol</source> <year>2010</year>; <volume>17</volume>(<issue>2</issue>): <fpage>13</fpage>–<lpage>23</lpage>.</citation></ref>
<ref id="bibr4-1078155212458133"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>N</given-names></name><name><surname>Jacoulet</surname><given-names>P</given-names></name><name><surname>Gainet</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice</article-title>. <source>Thorac Oncol</source> <year>2009</year>; <volume>4</volume>(<issue>12</issue>): <fpage>1544</fpage>–<lpage>1549</lpage>.</citation></ref>
<ref id="bibr5-1078155212458133"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Wakelee</surname><given-names>H</given-names></name></person-group>. <article-title>Second and third-line treatments in non-small cell lung cancer</article-title>. <source>Curr Treat Options Oncol</source> <year>2006</year>; <volume>7</volume>(<issue>1</issue>): <fpage>37</fpage>–<lpage>49</lpage>.</citation></ref>
<ref id="bibr6-1078155212458133"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavelle</surname><given-names>F</given-names></name><name><surname>Bissery</surname><given-names>MC</given-names></name><name><surname>Andre</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Preclinical evaluation of CPT-11 and its active metabolite SN-38</article-title>. <source>Semin Oncol</source> <year>1996</year>; <volume>23</volume>(<issue>Suppl. 3</issue>): <fpage>11</fpage>–<lpage>20</lpage>.</citation></ref>
<ref id="bibr7-1078155212458133"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>AJ</given-names></name><name><surname>Cosby</surname><given-names>LA</given-names></name><name><surname>Shansky</surname><given-names>CW</given-names></name><etal/></person-group>. <article-title>Potential bioreductive alkylating agents: 1. Benzoquinone derivatives</article-title>. <source>J Med Chem</source> <year>1972</year>; <volume>15</volume>(<issue>12</issue>): <fpage>1247</fpage>–<lpage>1252</lpage>.</citation></ref>
<ref id="bibr8-1078155212458133"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>DG</given-names></name><name><surname>Johnson</surname><given-names>DH</given-names></name><name><surname>Azzoli</surname><given-names>CG</given-names></name><etal/></person-group>. <article-title>American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline</article-title>. <source>J Clin Oncol</source> <year>2004</year>; <volume>22</volume>(<issue>2</issue>): <fpage>330</fpage>–<lpage>353</lpage>.</citation></ref>
<ref id="bibr9-1078155212458133"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cullen</surname><given-names>MH</given-names></name><name><surname>Billingham</surname><given-names>LJ</given-names></name><name><surname>Woodroffe</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Mitomycin, ifosfamide and cisplatin in unresectable non–small-cell lung cancer: effects on survival and quality of life</article-title>. <source>J Clin Oncol</source> <year>1999</year>; <volume>17</volume>(<issue>10</issue>): <fpage>3188</fpage>–<lpage>3194</lpage>.</citation></ref>
<ref id="bibr10-1078155212458133"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carretta</surname><given-names>A</given-names></name><name><surname>Chiesa</surname><given-names>O</given-names></name><name><surname>Zannini</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Surgery following neoadjuvant MPV chemotherapy (mitomycin, cisplatin, vinblastine) in locally advanced (IIIa and IIIb) non-small cell lung cancer</article-title>. <source>Eur J Cardiothorac Surg</source> <year>1994</year>; <volume>8</volume>(<issue>9</issue>): <fpage>457</fpage>–<lpage>461</lpage>.</citation></ref>
<ref id="bibr11-1078155212458133"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosmas</surname><given-names>C</given-names></name><name><surname>Tsavaris</surname><given-names>N</given-names></name><name><surname>Syrigos</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens</article-title>. <source>Cancer Chemother Pharmacol</source> <year>2007</year>; <volume>59</volume>(<issue>1</issue>): <fpage>51</fpage>–<lpage>59</lpage>.</citation></ref>
<ref id="bibr12-1078155212458133"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jazieh</surname><given-names>AR</given-names></name><name><surname>Komrokji</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer</article-title>. <source>Cancer Invest</source> <year>2009</year>; <volume>27</volume>(<issue>9</issue>): <fpage>932</fpage>–<lpage>936</lpage>.</citation></ref>
<ref id="bibr13-1078155212458133"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukuoka</surname><given-names>M</given-names></name><name><surname>Niitani</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CPT-11 Lung Cancer Study Group. A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small lung cancer</article-title>. <source>J Clin Oncol</source> <year>1992</year>; <volume>10</volume>: <fpage>16</fpage>–<lpage>20</lpage>.</citation></ref>
<ref id="bibr14-1078155212458133"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kano</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Akutsu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effects of CPT-11 in combination with other anti-cancer agents in culture</article-title>. <source>Int J Cancer</source> <year>1992</year>; <volume>50</volume>: <fpage>604</fpage>–<lpage>610</lpage>.</citation></ref>
<ref id="bibr15-1078155212458133"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villalona-Calero</surname><given-names>MA</given-names></name><name><surname>Kolesar</surname><given-names>JM</given-names></name></person-group>. <article-title>Mitomycin as a modulator of irinotecan anticancer activity</article-title>. <source>Oncology</source> <year>2002</year>; <volume>16</volume>: <fpage>21</fpage>–<lpage>25</lpage>.</citation></ref>
<ref id="bibr16-1078155212458133"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Kolesar</surname><given-names>JM</given-names></name><name><surname>Schaaf</surname><given-names>LJ</given-names></name><etal/></person-group>. <article-title>Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies</article-title>. <source>Cancer Chemother Pharmacol</source> <year>2009</year>; <volume>63</volume>(<issue>6</issue>): <fpage>1073</fpage>–<lpage>1082</lpage>.</citation></ref>
<ref id="bibr17-1078155212458133"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oken</surname><given-names>MM</given-names></name><name><surname>Creech</surname><given-names>RH</given-names></name><name><surname>Tormey</surname><given-names>DC</given-names></name><etal/></person-group>. <article-title>Toxicity and response criteria of the eastern cooperative oncology group</article-title>. <source>Am J Clin Oncol</source> <year>1982</year>; <volume>5</volume>: <fpage>649</fpage>–<lpage>655</lpage>.</citation></ref>
<ref id="bibr18-1078155212458133"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamao</surname><given-names>T</given-names></name><name><surname>Shirao</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Phase I–II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer</article-title>. <source>Annals of Oncology</source> <year>2001</year>; <volume>12</volume>: <fpage>1729</fpage>–<lpage>1735</lpage>.</citation></ref>
<ref id="bibr19-1078155212458133"><label>19</label><citation citation-type="other"><comment>Common Toxicity Criteria and Terminology Criteria for Adverse Events (CTCAE) Version 4.0. National Cancer Institute. <ext-link ext-link-type="uri" xlink:href="http://evs.nci.nih.gov/ftp1/CTCAE/About.html">http://evs.nci.nih.gov/ftp1/CTCAE/About.html</ext-link> (accessed 7 August 2012)</comment>.</citation></ref>
<ref id="bibr20-1078155212458133"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><etal/></person-group>. <article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title>. <source>J Natl Cancer Inst</source> <year>2000</year>; <volume>92</volume>: <fpage>205</fpage>–<lpage>216</lpage>.</citation></ref>
<ref id="bibr21-1078155212458133"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verwey</surname><given-names>J</given-names></name><name><surname>de Vries</surname><given-names>J</given-names></name><name><surname>Pinedo</surname><given-names>HM</given-names></name></person-group>. <article-title>Mitomycin C-induced renal toxicity, a dose-dependent side effect?</article-title> <source>Eur J Cancer Clin Oncol</source> <year>1987</year>; <volume>23</volume>(<issue>2</issue>): <fpage>195</fpage>–<lpage>199</lpage>.</citation></ref>
<ref id="bibr22-1078155212458133"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scagliotti</surname><given-names>GV</given-names></name><name><surname>Parikh</surname><given-names>P</given-names></name><name><surname>von Pawel</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source> <year>2008</year>; <volume>26</volume>(<issue>21</issue>): <fpage>3543</fpage>–<lpage>3551</lpage>.</citation></ref>
<ref id="bibr23-1078155212458133"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Perry</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>355</volume>: <fpage>2542</fpage>–<lpage>2550</lpage>.</citation></ref>
<ref id="bibr24-1078155212458133"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaughan</surname><given-names>EM</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name></person-group>. <article-title>Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities</article-title>. <source>Ther Adv Med Oncol</source> <year>2011</year>; <volume>3</volume>(<issue>3</issue>): <fpage>113</fpage>–<lpage>125</lpage>.</citation></ref>
<ref id="bibr25-1078155212458133"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldini</surname><given-names>E</given-names></name><name><surname>Tibaldi</surname><given-names>C</given-names></name><name><surname>Ardizzoni</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase 11 study. Italian Lung Cancer Task Force (FONICAP)</article-title>. <source>Br J Cancer</source> <year>1998</year>; <volume>77</volume>(<issue>12</issue>): <fpage>2367</fpage>–<lpage>2370</lpage>.</citation></ref>
<ref id="bibr26-1078155212458133"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>RJ</given-names></name><name><surname>Girling</surname><given-names>DJ</given-names></name><name><surname>Hopwood</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer</article-title>. <source>Lung Cancer</source> <year>2005</year>; <volume>49</volume>(<issue>3</issue>): <fpage>395</fpage>–<lpage>400</lpage>.</citation></ref>
<ref id="bibr27-1078155212458133"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sculier</surname><given-names>JP</given-names></name><name><surname>Ghisdal</surname><given-names>L</given-names></name><name><surname>Berghmans</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature</article-title>. <source>Br J Cancer</source> <year>2001</year>; <volume>84</volume>(<issue>9</issue>): <fpage>1150</fpage>–<lpage>1155</lpage>.</citation></ref>
</ref-list>
</back>
</article>